Maravai LifeSciences (MRVI) furnishes Q3 2025 results press release

Maravai LifeSciences Holdings, Inc. furnished an Item 2.02 report stating it issued a press release announcing financial results for the third quarter of 2025.

Accepted by SEC EDGAR 11/06/2025 - 04:03 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Maravai LifeSciences Holdings, Inc. furnished an Item 2.02 report stating it issued a press release announcing financial results for the third quarter of 2025. The press release is included as Exhibit 99.1. The company states this information is furnished, not filed, under the Exchange Act and is not incorporated by reference unless expressly specified.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Maravai LifeSciences (MRVI) announce in this 8-K?

It furnished a press release announcing financial results for the third quarter of 2025, included as Exhibit 99.1.

Where can I find MRVI’s Q3 2025 results details?

They are in the press release attached as Exhibit 99.1 to the report.

Is the Q3 2025 information considered filed or furnished?

It is furnished under Item 2.02 and is not deemed filed under the Exchange Act.

What exhibits accompany this report for MRVI?

Exhibit 99.1 (press release dated November 6, 2025) and Exhibit 104 (Cover Page Interactive Data File).

Who signed the report for Maravai LifeSciences (MRVI)?

It was signed by Rajesh Asarpota, Chief Financial Officer.

What is Maravai LifeSciences’ trading symbol and exchange?

The Class A common stock trades as MRVI on the Nasdaq Global Select Market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001823239FALSE00018232392025-11-062025-11-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 6, 2025

Maravai LifeSciences Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware

001-39725

85-2786970

(State or other jurisdiction of incorporation)

(Commission File Number)

(IRS Employer Identification No.)

10770 Wateridge Circle Suite 200 San Diego, California

92121

(Address of principal executive offices)

(Zip Code)

(858) 546-0004

(Registrant’s telephone number, including area code)

Not Applicable (Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Class A Common Stock, $0.01 par value

MRVI

The Nasdaq Stock Market LLC

(Nasdaq Global Select Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 6, 2025, Maravai LifeSciences Holdings, Inc. issued a press release announcing its financial results for the third quarter of 2025. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 2.02 of this Form 8-K and the Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.						Description of Exhibit
99.1*						Press Release dated November 6, 2025.
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

_______________

* Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly set forth by specific reference in such filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			MARAVAI LIFESCIENCES HOLDINGS, INC.
Date: November 6, 2025			By:			/s/ Rajesh Asarpota
			Name:			Rajesh Asarpota
			Title:			Chief Financial Officer